Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Amgen obesity drug on hold; Regeneron sets first dividend
Turnstone Biologics Announces Plans to Explore Strategic Alternatives
Turnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Warning: TSBX is at high risk of performing badly
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
